145.36MMarket Cap-867P/E (TTM)
2.250High2.075Low1.54MVolume2.150Open2.160Pre Close3.29MTurnover2.98%Turnover Ratio3.05P/E (Static)68.08MShares22.35852wk High0.56P/B110.20MFloat Cap1.57552wk Low--Dividend TTM51.61MShs Float41.930Historical High--Div YieldTTM8.10%Amplitude1.575Historical Low2.141Avg Price1Lot Size
Amylyx Pharmaceuticals Stock Forum
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for Amx0035 for the Treatment of Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delve...
Dow Jones· 11 mins ago! Is to enter Phase 3 Trial in Q1 2025!
No comment yet